NexturnBioscience Co. Ltd Cash Flow-to-Debt Ratio
NexturnBioscience Co. Ltd cash flow-to-debt ratio. NexturnBioscience Co. Ltd (089140) has a Cash Flow-to-Debt Ratio of 0.04x as of September 2025, meaning its operating cash flow of ₩4.51 Billion could theoretically repay 0% of its total liabilities (₩128.65 Billion) in one year. Check 089140 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of NexturnBioscience Co. Ltd (2014–2024)
Cash flow-to-debt ratio of NexturnBioscience Co. Ltd from 2014 to 2024. Historical debt coverage capacity for NexturnBioscience Co. Ltd across 11 annual periods. Check 089140 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
NexturnBioscience Co. Ltd Cash Flow-to-Debt Ratio by Year (2014–2024)
NexturnBioscience Co. Ltd cash flow-to-debt ratio by year from 2014 to 2024. Year-by-year debt coverage analysis for NexturnBioscience Co. Ltd. For the full cash flow conversion analysis, see cash efficiency ratio of NexturnBioscience Co. Ltd.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.01x | ₩-1.14 Billion | ₩96.41 Billion | ▲ +36.2% |
| 2023 | -0.02x | ₩-1.97 Billion | ₩105.98 Billion | ▼ -43.6% |
| 2022 | -0.01x | ₩-1.19 Billion | ₩91.98 Billion | ▼ -116.3% |
| 2021 | 0.08x | ₩3.66 Billion | ₩46.21 Billion | ▼ -13.2% |
| 2020 | 0.09x | ₩235.94 Million | ₩2.58 Billion | ▼ -83.3% |
| 2019 | 0.55x | ₩2.74 Billion | ₩5.01 Billion | ▲ +2.1% |
| 2018 | 0.53x | ₩9.63 Billion | ₩18.01 Billion | ▼ -68.6% |
| 2017 | 1.70x | ₩5.08 Billion | ₩2.99 Billion | ▼ -17.8% |
| 2016 | 2.07x | ₩17.88 Billion | ₩8.64 Billion | ▲ +242.1% |
| 2015 | 0.60x | ₩1.92 Billion | ₩3.17 Billion | ▼ -58.9% |
| 2014 | 1.47x | ₩6.48 Billion | ₩4.41 Billion | — |